CD8A and neoplasm: Within dLNs, the nanodevice can respond to and release antigens and adjuvants in an acidic environment, activate dendritic cells, and elicit a robust, tumor-specific CD8+ CTL response via the Toll-like receptor (TLR) pathway and antigenic peptide presentation[58].